Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy

Bispecific antibodies are of great interest due to their ability to simultaneously bind and engage different antigens or epitopes. Nevertheless, it remains a challenge to assemble, produce and/or purify them. Here we present an innovative dual anti-idiotypic purification process, which provides pure...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2016-08, Vol.6 (1), p.31621-31621, Article 31621
Main Authors: Godar, Marie, Morello, Virginia, Sadi, Ava, Hultberg, Anna, De Jonge, Natalie, Basilico, Cristina, Hanssens, Valérie, Saunders, Michael, Lambrecht, Bart N., El Khattabi, Mohamed, de Haard, Hans, Michieli, Paolo, Blanchetot, Christophe
Format: Article
Language:English
Subjects:
13
13/31
631/61/338/469
64
64/60
692/4028
82/1
82/103
82/58
82/83
Humanities and Social Sciences
multidisciplinary
Science
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bispecific antibodies are of great interest due to their ability to simultaneously bind and engage different antigens or epitopes. Nevertheless, it remains a challenge to assemble, produce and/or purify them. Here we present an innovative dual anti-idiotypic purification process, which provides pure bispecific antibodies with native immunoglobulin format. Using this approach, a biparatopic IgG1 antibody targeting two distinct, HGF-competing, non-overlapping epitopes on the extracellular region of the MET receptor, was purified with camelid single-domain antibody fragments that bind specifically to the correct heavy chain/light chain pairings of each arm. The purity and functionality of the anti-MET biparatopic antibody was then confirmed by mass spectrometry and binding experiments, demonstrating its ability to simultaneously target the two epitopes recognized by the parental monoclonal antibodies. The improved MET-inhibitory activity of the biparatopic antibody compared to the parental monoclonal antibodies, was finally corroborated in cell-based assays and more importantly in a tumor xenograft mouse model. In conclusion, this approach is fast and specific, broadly applicable and results in the isolation of a pure, novel and native-format anti-MET biparatopic antibody that shows superior biological activity over the parental monospecific antibodies both in vitro and in vivo .
ISSN:2045-2322
2045-2322
DOI:10.1038/srep31621